Skip to main content

Table 5 Hormonal parameters

From: Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients

Parameter (normal range)

Months

 

T0

T3

T6

T12

TT (3.5-8.5 ng/mL)

1.16 ± 0.28

2.72 ± 0.69**

2.18 ± 0.51*

2.99 ± 0.47**

fT (14.7-32.7 pg/mL)

4.33 ± 0.89

7.55 ± 2.34

6.76 ± 1.79

10.57 ± 1.88*

BioT (ng/dL)

0.34 ± 0.1

0.94 ± 0.28*

0.96 ± 0.45*

1.17 ± 0.34*

SHBG (28-94 nmol/L)

77.77 ± 12.12

89.41 ± 20.0

79.76 ± 15.7

54.15 ± 7.22

% fT

0.41 ± 0.04

0.31 ± 0.06

0.31 ± 0.02

0.36 ± 0.04

DHT (250-750 pg/mL)

248.65 ± 32.10

903.7 ± 321.9

582.45 ± 125.9

796.04 ± 137.22*

E2 (10-25 pg/mL)

10.84 ± 1.23

11.65 ± 1.09

12.03 ± 1.71

12.43 ± 2.13

DHT/TT

0.29 ± 0.03

0.28 ± 0.04

0.27 ± 0.02

0.29 ± 0.038

E2/TT

0.01 ± 0.003

0.006 ± 0.001**

0.007 ± 0.0007*

0.005 ± 0.001**

C (50-250 ng/mL)

164.04 ± 30.72

150.2 ± 22.1

131.58 ± 19.74

129.97 ± 15.57

  1. TT: total testosterone, fT: free testosterone; BioT: bioavailable testosterone; SHBG: steroid hormone binding globuline; %fT: percentage of free testosterone; DHT: dehydrotestosterone; E2: estradiol; C: cortisol. Hormone levels determined before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy. Values are mean ± SEM (n = 9). Wilcoxon test: * p < 0.05 vs T0; ** p < 0.01 vs T0.